Press release
Alzheimer's Disease Diagnostics Market Set to Grow at 11.60% CAGR, Reaching USD 20.98 Billion by 2033
Alzheimer's Disease Diagnostics Market
The study offers comprehensive coverage of the qualitative and quantitative analysis of the Alzheimer's Disease Diagnostics market along with crucial statistical data about the Alzheimer's Disease Diagnostics market. The research study provides historical data from 2024 to 2032 and offers accurate forecast estimation until 2032. The report also profiles established and emerging players of the market, covering the business overview, product portfolio, strategic alliances, and business expansion strategies.
The Alzheimer's Disease Diagnostics market is forecasted to experience significant growth, increasing from an estimated USD 7.81 billion in 2024 to USD 20.98 billion by 2033, at a robust CAGR of 11.60%. This growth is driven by advancements in diagnostic technologies, rising awareness of early detection, and the increasing prevalence of dementia worldwide.
Get Free Sample PDF Copy Of This Report@ https://www.emergenresearch.com/request-sample/3586
Advancements in Diagnostics Drive Innovation
The Alzheimer's diagnostics market is witnessing a surge in innovation fueled by breakthroughs in biomarkers and neuroimaging techniques. These technologies enable more accurate and early diagnosis, facilitating timely intervention and personalized treatment. Key advancements include combining blood and cerebrospinal fluid biomarkers with neuroimaging to improve diagnostic precision. For instance, in April 2024, Quest Diagnostics introduced a new blood biomarker test for phosphorylated tau 217 (p-tau217), marking a significant step forward in blood-based Alzheimer's diagnostics.
In addition, companies are expanding their diagnostic portfolios with tools such as cerebrospinal fluid testing, genetic diagnostics, and blood-based biomarkers, ensuring a comprehensive approach to brain health. These ongoing efforts are expected to sustain high levels of innovation in the market over the coming years.
Regulatory Advancements Support Growth
Regulations play a pivotal role in shaping the Alzheimer's diagnostics landscape. Updates in diagnostic criteria and regulatory standards are enhancing the credibility of diagnostic tests and driving market growth. In July 2024, the Alzheimer's Association emphasized the adoption of new diagnostic criteria developed in collaboration with the National Institute on Aging (NIA). These revised guidelines, based on recent scientific and technological developments, aim to improve diagnosis accuracy and set the stage for future research advancements.
Drivers and Challenges in the Market
The increasing prevalence of dementia is a major driver of the Alzheimer's diagnostics market. With aging populations worldwide, effective diagnostic solutions are in higher demand to address cognitive diseases. According to the World Alzheimer Report, approximately 50 million people were living with dementia in 2022, a number projected to rise to 152 million by 2050. Additionally, growing awareness among healthcare providers and patients about the importance of early detection is fostering investment and innovation in diagnostic technologies.
However, the market faces challenges due to limited treatment options. While diagnostic tools have advanced significantly, the lack of effective therapies to halt or reverse Alzheimer's progression limits the perceived value of early detection. This challenge can deter investment in diagnostics, slowing market growth.
Segment Insights: Biomarkers and Imaging Techniques Lead the Market
The Alzheimer's diagnostics market is segmented into biomarkers, imaging techniques, genetic testing, and cognitive assessment tests. Among these, imaging techniques accounted for the largest revenue share in 2023. Technologies such as computed tomography (CT), positron emission tomography (PET), and functional MRI (fMRI) have become essential tools for early and accurate disease diagnosis, helping detect critical changes like amyloid plaques and brain atrophy.
The biomarkers segment is expected to experience the fastest growth during the forecast period. This is driven by a growing demand for both cerebrospinal fluid (CSF) biomarkers and blood-based biomarkers to diagnose and monitor Alzheimer's. CSF biomarkers, including amyloid-beta (Aβ), tau, and neurofilament light chain (NfL), are widely used in clinical practice. Meanwhile, blood-based biomarkers are emerging as a promising option for predicting Alzheimer's through simple blood tests. These developments make biomarkers a focal point for future innovation in the industry.
Request For Customization: https://www.emergenresearch.com/request-for-customization/3586
Competitive Terrain:
The global Alzheimer's Disease Diagnostics industry is highly consolidated owing to the presence of renowned companies operating across several international and local segments of the market. These players dominate the industry in terms of their strong geographical reach and a large number of production facilities. The companies are intensely competitive against one another and excel in their individual technological capabilities, as well as product development, innovation, and product pricing strategies.
Leading Market Players Profiled in the Report:
Quest Diagnostics
Labcorb
C2N diagnostics
FujireBio
Bristol Myers Squibb
Hoffmann-La Roche
Quanterix
Sysmex
Lantheus
Siemens Healthineers
Report Highlights:
Besides offering a vivid depiction of the global Alzheimer's Disease Diagnostics business sphere and its fundamental operations, the latest report provides the industrial chain analysis and list down the current and future market trends and growth opportunities.
The report includes information on the present and historical market scenarios, which helps forecast the market conditions over the next eight years (2024-2033).
The report scrutinizes the salient factors influencing the growth of the market in the near future.
The strategic marketing recommendations, crucial information related to the new market entrants, and expansion plans of various businesses are poised to provide the reader with a competitive edge in the market.
The global Alzheimer's Disease Diagnostics market report covers the analysis of drivers, trends, limitations, restraints, and challenges arising in the Alzheimer's Disease Diagnostics market. The report also discusses the impact of various other market factors affecting the growth of the market across various segments and regions. The report segments the market on the basis of types, applications, and regions to impart a better understanding of the Alzheimer's Disease Diagnostics market.
Alzheimer's Disease Diagnostics Market Segmentation Analysis
Diagnostics Technique Outlook (Revenue, USD Billion; 2020-2033)
Biomarkers
CSF Biomarkers
Blood-Based Biomarkers
Imaging Techniques
Genetic Testing
Cognitive Assessment Tests
Type Outlook (Revenue, USD Billion; 2020-2033)
Triage
Diagnosis
Screening
End-use Outlook (Revenue, USD Billion; 2020-2033)
Hospitals
Diagnostic Laboratories
Academic and Research Institutes
Browse Full Report@ https://www.emergenresearch.com/industry-report/alzheimer-disease-diagnostics-market
Regional Outlook:
North America (the U.S., Canada, Mexico)
Europe (the U.K., Germany, France, Italy)
Asia Pacific (India, China, Japan, Korea)
Latin America (Brazil, Argentina, Ecuador, Chile)
Middle East & Africa (Egypt, Turkey, Saudi Arabia, Iran)
The study will prove useful for leading companies looking to find new sources of income by helping them to understand the market and its underlying dynamics. It will also be useful for businesses looking to expand into new markets or diversify their current operations.
How will this Report Benefit you?
An Emergen Research report of 250 pages contains 194 tables, 189 charts and graphics, and anyone who needs a comprehensive analysis of the global Alzheimer's Disease Diagnostics market, as well as commercial, in-depth analyses of the individual segments, will find the study useful. Our recent study allows you to assess the entire regional and global market for Alzheimer's Disease Diagnostics. In order to increase market share, obtain financial analysis of each segment and the whole market.
Thank you for reading our report. For further details or to inquire about customization, please let us know and we will offer you the report as per your needs.
14671 110 Avenue, Surrey, British Columbia, V3R2A9
Eric Lee
Corporate Sales Specialist
Emergen Research | Web: www.emergenresearch.com
Direct Line: +1 (604) 757-9756
E-mail: sales@emergenresearch.com
Emergen Research is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyse consumer behavior shifts across demographics, across industries, and help clients make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Types, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Emergen Research has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Alzheimer's Disease Diagnostics Market Set to Grow at 11.60% CAGR, Reaching USD 20.98 Billion by 2033 here
News-ID: 3854435 • Views: …
More Releases from Emergen Research
Global Internet of Things (IoT) in Healthcare Market to Reach USD 299.05 Billion …
The global Internet of Things (IoT) in Healthcare Market was valued at USD 299.05 billion in 2023 and is expected to grow at a CAGR of 16.5% during the forecast period. This growth is fueled by the rising use of connected healthcare devices, increasing demand for early disease detection through remote monitoring, and growing adoption of artificial intelligence (AI) tools within IoT-based healthcare systems.
The market is also benefiting from the…
Global Stem Cell Therapy Market to Reach USD 49.2 Billion by 2034, Growing at 13 …
The global Stem Cell Therapy Market, valued at USD 13.7 billion in 2024, is projected to reach USD 49.2 billion by 2034, expanding at a compound annual growth rate (CAGR) of 13.6%. Growth is being fueled by the rising burden of chronic diseases, rapid progress in cell-based studies, and increasing investments in regenerative medicine and personalized healthcare solutions.
Stem cell therapies offer the ability to repair, replace, or restore damaged tissues…
Artificial Intelligence Strengthens Cybersecurity as Threats Grow More Sophistic …
The global Artificial Intelligence in cybersecurity market size was USD 23.8 Billion in 2023 and is expected to reach a market valuation of USD 29.44 billion by the end of 2024 registering a CAGR of 23.7% during the forecast period. The adoption of Artificial Intelligence (AI) in cybersecurity is rapidly gaining traction as organizations worldwide face increasingly complex and frequent cyber threats. By combining advanced technologies such as Machine Learning…
Global Regenerative Medicine Market to Reach USD 125.6 Billion by 2034, Growing …
The global regenerative medicine market, valued at USD 34.2 billion in 2024, is set to grow to USD 125.6 billion by 2034, expanding at a compound annual growth rate (CAGR) of 13.9%. Growth is being fueled by rising approvals of advanced therapies, strong demand for personalized treatments in cancer and orthopedics, and expanding cell and gene therapy manufacturing across major markets such as North America, Europe, and Asia.
Once seen as…
More Releases for Alzheimer
Dementia - Alzheimer Disease Market: A Comprehensive Analysis 2030
Dementia and Alzheimer's disease represent significant challenges within the global healthcare sector. These neurological disorders, characterized by progressive cognitive decline, have seen increasing prevalence due to aging populations worldwide. This growing burden has spurred interest in the Dementia - Alzheimer's disease market, encompassing diagnostic tools, treatments, caregiving solutions, and related healthcare services. This article provides an overview of the market, its scope, current trends, and factors driving its expansion.
Data Bridge…
Alzheimer Disease Treatment Market | Allergan, Amgen, Daiichi Sankyo, Eisai
The global alzheimer disease treatment market report is a comprehensive report that provides a detailed analysis of the current status and future trends of the alzheimer disease treatment market worldwide. This report provides valuable information to industry stakeholders by offering an in-depth perspective on market dynamics, competitive landscape, growth opportunities, and key challenges faced by industry participants.
From the perspective of market dynamics, this report explores the factors driving the growth…
United States Alzheimer Drugs Market Insights Deep Analysis 2023-2031
Cognate Life Sciences introduces a report on "United States Alzheimer Drugs Market 2023" with Market Insights Reports, Introduces systematic details in terms of market valuation, market size, revenue estimation, and geographical spectrum of the business vertical. The study also talks about crucial pockets of the industry such as products or services offered, downstream fields, end using customers, historic data figures regarding revenue and sales, market context and more. It conjointly…
Global Alzheimer Market, Global Alzheimer Industry, Covid-19 Impact Global Alzhe …
Alzheimer's is a progressive disease that leads to the death of brain cells, resulting in memory loss, behavioral issues, and disruption the thought processes. The Alzheimer disease is considered fatal. Age and heredity are the two main risk factors for developing Alzheimer's disease. Several other preventable risk factors have been associated to the development of this disease, including diet, environment, and overall general health. A combination of risk factors is…
US Alzheimer Drug Pipeline Analysis
In US, the Alzheimer's disease is the 6th leading cause of death overall and among those aged 65 and above, it is the 5th leading cause of death. While the deaths from major diseases, like heart disease have decreased, the death due to Alzheimer's have increased by more than 60% between 2000 and 2012. The total number of patients having Alzheimer’s disease was 5.4 million in 2012. Out of this,…
Global Alzheimer Market Report: 2015 Edition | Now Available at Researchmoz.us
Researchmoz added Most up-to-date research on "Global Alzheimer Market Report: 2015 Edition" to its huge collection of research reports.
Alzheimer’s disease is defined as an advanced neurological disorder that increasingly deprives patients of their memory and ability to carry out daily activities. As it grows in a human brain, individuals are likely to practice difficulties in linguistic, agility and insight along with negative changes in the character and performance such as…
